$IMGO News

Last published 1y ago

1y agoBBNX BCAX KMTS MORF+2Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science CompaniesBusiness WireOmega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The
3y agoIMGO MRKMerck Completes Tender Offer to Acquire Imago BioSciences, Inc.Business WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of
3y agoIMGOImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in MyelofibrosisGlobeNewswireREDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the
3y agoIMGOImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022GlobeNewswire- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients
3y agoIMGOImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022GlobeNewswire- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this
3y agoIMGO MRKMerck Begins Tender Offer to Acquire Imago BioSciences, Inc.Business WireMerck (NYSE:MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc.
3y agoIMGOImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid LeukemiaGlobeNewswireREDWOOD CITY, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of
3y agoOXY FANG COIN CVNA+13Stocks making the biggest moves midday: Disney, Carvana, Diamondback Energy and moreCNBCThese are the stocks posting the largest moves in midday trading.
3y agoDIS CVNA COIN SJM+8Stocks making the biggest moves in the premarket: Walt Disney, Carvana, Coinbase and moreCNBCThe stocks making the biggest moves in premarket trading include Walt Disney, Carvana, Coinbase, and more.
3y agoIMGO MRKMerck to Acquire Imago BioSciences, Inc.Business WireAcquisition expands Merck's growing hematology portfolio Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO) today announced that the companies have
4y agoIMGOImago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business UpdatesGlobeNewswire- Data updates for Bomedemstat Phase 2 trials in Essential Thrombocythemia (ET) and Myelofibrosis (MF) to be presented at the American Society of Hematology (ASH) Annual Meeting in December 2022 - - Start-up activities
4y agoIMGOImago BioSciences to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of
4y agoIMGOImago BioSciences Announces Oral Data Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and ExpositionGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of
4y agoIMGOImago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs
4y agoIMGOImago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business UpdatesGlobeNewswire- Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia (ET) Presented at European Hematology Association (EHA) Meeting 2022 - - Positive Data from the Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis P
4y agoIMGOImago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs)
4y agoIMGOImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at EHA 2022GlobeNewswire- The study completed enrollment with 73 patients in April 2022 - - As of the data cutoff of 29 April 2022, bomedemstat demonstrated durability of response with 81% of patients achieving normalized platelet counts for at least 12 weeks - - 58% of p
4y agoIMGOImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at EHA 2022GlobeNewswire- As of the data cutoff date of 29 April 2022, in addition to improvements in the standard metrics of spleen volume reduction and symptom scores, long term treatment with bomedemstat showed: 52% had reductions in mutant allele frequencies, including
4y agoIMGOImago BioSciences to Host Virtual Investor EventGlobeNewswire- Company to host virtual investor event on Saturday, June 11 at 10:30 AM ET following its June 10th presentation of updated data from Phase 2 studies of bomedemstat for the treatment of Essential Thrombocythemia and Myelofibrosis at the 2022 European He
4y agoIMGOImago BioSciences to Participate in Upcoming Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPN
4y agoIMGOImago BioSciences Reports First Quarter 2022 Financial Results and Provides Recent Business UpdatesGlobeNewswire- Completed Type C meeting with FDA to align on study design, study population, control group and primary endpoint for planned Phase 3 essential thrombocythemia (ET) study - Enrollment completed in Phase 2 trial of bomedemstat for treatment of ET
4y agoIMGOImago BioSciences Announces Upcoming Presentations on Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at the 27th Congress of the European Hematology Association (EHA) for 2022GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs)
4y agoIMGOImago BioSciences Announces First Participant Dosed in Investigator-Sponsored Study of Bomedemstat in Combination with Atezolizumab in Small Cell Lung CancerGlobeNewswireSOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs)
4y agoIMGOImago BioSciences Announces Completion of Enrollment in Phase 2 Clinical Study of Bomedemstat in Essential ThrombocythemiaGlobeNewswireInterim Data Update at European Hematology Association (EHA) meeting in June and Results from Completed Phase 2 Study Expected in Second Half of 2022 End-of-Phase 2 Meeting with U.S. Food and Drug Administration (FDA) Expected in Second Half of 2
4y agoIMGOImago BioSciences Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other
4y agoIMGOImago BioSciences Appoints Michael Arenberg to Chief Operating and Business OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today annou
4y agoIMGOImago BioSciences to Participate in the Cowen 42nd Annual Health Care ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today anno
4y agoIMGOImago BioSciences to Participate in Guggenheim Healthcare Talks 2022 Oncology ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announc
4y agoIMGO IMRXPepGen Appoints Laurie Keating as Chair of Board of DirectorsGlobeNewswireBOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed Laurie Keating as Chair of the company's Board of Di
4y agoADGI ICVX IKNA IMGO+5Omega Funds Closes Oversubscribed $650 Million Fund VII to Invest in Transformative Life Science CompaniesPR NewswireBOSTON, Dec. 17, 2021 /PRNewswire/ -- Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced it has closed its seventh and largest fund with $650 million in limited part
4y agoIMGOImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2021Business Wire- Expanded Phase 2 data set continues to provide compelling rationale for move to registrational clinical program - - Bomedemstat demonstrated durable clinical improvement in patients with ET who failed at least one standard therapy (usually hydroxyu
4y agoIMGOImago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2021Business Wire- Bomedemstat continues to be generally well-tolerated - - Bomedemstat demonstrated encouraging and distinct clinical benefit to patients with advanced myelofibrosis - - Data highlights rationale for bomedemstat as potential MF mono- or combinatio
4y agoIMGOImago BioSciences to Host Virtual Investor EventGlobeNewswireSOUTH SAN FRANCISCO, Calif., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago" or the "Company") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (
4y agoIMGOImago BioSciences Appoints Laurie Keating to Board of DirectorsBusiness WireImago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Laurie Keating to its Board of Directors
5y agoIMGOImago BioSciences to Present at Stifel 2021 Virtual Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announc
5y agoIMGOImago BioSciences Reports Third Quarter 2021 Financial Results and Provides Recent Business UpdatesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical-stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reporte
5y agoIMGOImago BioSciences Announces Oral Data Presentations at the Upcoming 63rd American Society of Hematology Annual Meeting and ExpositionBusiness WireImago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced two abstracts have been accepted for oral presentation at the 6
5y agoIMGOImago BioSciences Announces Its Addition to the Russell 2000® IndexBusiness WireImago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that it will be added to the Russell® 2000 Index as part of
5y agoIMGOImago BioSciences Reports Second Quarter 2021 Financial Results and Provides Recent Business UpdatesBusiness WireImago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today reported financial results for the second quarter ended June 30, 2021 a
5y agoIMGOImago BioSciences Receives Orphan Designation From European Medicines Agency for Bomedemstat for the Treatment of Essential ThrombocythemiaBusiness WireImago BioSciences, Inc. (Imago) (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that the European Medicines Agency (EMA) has granted orphan des
5y agoIMGOImago BioSciences, Inc. Announces Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireImago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that in connection with its previously announced public offer
5y agoIMGOImago BioSciences, Inc. Announces Closing of $134.4 Million Initial Public OfferingBusiness WireImago BioSciences, Inc. ("Imago") (NASDAQ:IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the closing of $134.4 million in gross proceeds from its prev
5y agoIMGOImago BioSciences, Inc. Announces Pricing of Upsized Initial Public Offering of Common StockBusiness WireImago BioSciences, Inc. ("Imago"), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the pricing of its upsized initial public offering of 8,400,000 shares of c